TY - JOUR
T1 - Proceedings of the Online Conference “Vaccines and Vaccination during and Post COVID Pandemics” (7–9 December 2022)
AU - Sokolovska, Liba
AU - Isaguliants, Maria
AU - Buonaguro, Franco M.
N1 - Funding Information:
The online conference VAC&VAC 2022 gathered about 150 participants from Latvia, Sweden, Italy, the USA, South Korea, South Africa, Netherlands, China, India, Tanzania, Denmark, Germany, Lithuania, and San Marino. Among the participants were academic researchers, public health specialists, and industry representatives, and one-fourth were medical students and PhD students. The conference was supported by the Latvian Council of Science grant 2021/1-0484, Riga Stradins University, the National Cancer Institute “Fondazione Pascale” (Naples, Italy), the International Society for Vaccines ( https://isv-online.org/ , accessed on 27 June 2023), and the MDPI Journal Vaccines.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/7
Y1 - 2023/7
N2 - The COVID-19 pandemic put focus on various aspects of vaccine research and development. These include mass vaccination strategies, vaccination compliance and hesitancy, acceptance of novel vaccine approaches, preclinical and animal models used to assess vaccine safety and efficacy, and many other related issues. These issues were addressed by the international online conference “Vaccines and Vaccination During and Post COVID Pandemics” (VAC&VAC 2022) held on the platform of Riga Stradins University, Riga, Latvia. Conference was supported by the International Society for Vaccines, the National Cancer Institute “Fondazione Pascale” (Naples, Italy), and the scientific journal VACCINES (mdpi). VAC&VAC 2022 attracted nearly 150 participants from 14 countries. This report summarizes conference presentations and their discussion. Sessions covered the topics of (1) COVID-19 vaccine development, evaluation, and attitude towards these vaccines, (2) HPV and cancer vaccines, (3) progress and challenges of HIV vaccine development, (4) new and re-emerging infectious threats, and (5) novel vaccine vehicles, adjuvants, and carriers. Each session was introduced by a plenary lecture from renowned experts from leading research institutions worldwide. The conference also included sessions on research funding and grant writing and an early career researcher contest in which the winners received monetary awards and a chance to publish their results free of charge in the special issue of VACCINES covering the meeting.
AB - The COVID-19 pandemic put focus on various aspects of vaccine research and development. These include mass vaccination strategies, vaccination compliance and hesitancy, acceptance of novel vaccine approaches, preclinical and animal models used to assess vaccine safety and efficacy, and many other related issues. These issues were addressed by the international online conference “Vaccines and Vaccination During and Post COVID Pandemics” (VAC&VAC 2022) held on the platform of Riga Stradins University, Riga, Latvia. Conference was supported by the International Society for Vaccines, the National Cancer Institute “Fondazione Pascale” (Naples, Italy), and the scientific journal VACCINES (mdpi). VAC&VAC 2022 attracted nearly 150 participants from 14 countries. This report summarizes conference presentations and their discussion. Sessions covered the topics of (1) COVID-19 vaccine development, evaluation, and attitude towards these vaccines, (2) HPV and cancer vaccines, (3) progress and challenges of HIV vaccine development, (4) new and re-emerging infectious threats, and (5) novel vaccine vehicles, adjuvants, and carriers. Each session was introduced by a plenary lecture from renowned experts from leading research institutions worldwide. The conference also included sessions on research funding and grant writing and an early career researcher contest in which the winners received monetary awards and a chance to publish their results free of charge in the special issue of VACCINES covering the meeting.
KW - adjuvants
KW - cancer
KW - cancer vaccine
KW - COVID-19 pandemic
KW - HBV
KW - high-risk HPV
KW - HIV-1
KW - vaccine hesitancy
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85166426824&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/47b156d7-5df8-387c-a628-50cd791192c9/
U2 - 10.3390/vaccines11071175
DO - 10.3390/vaccines11071175
M3 - Article
AN - SCOPUS:85166426824
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 7
M1 - 1175
ER -
